An Open-Label, Single-Center, Randomized, Parallel-Group, Single-Dose Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants
Latest Information Update: 12 Apr 2025
At a glance
- Drugs Bimekizumab (Primary)
- Indications Ankylosing spondylitis; Axial spondyloarthritis; Hidradenitis suppurativa; Plaque psoriasis; Psoriatic arthritis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors UCB Biopharma
Most Recent Events
- 12 Aug 2021 Status changed from suspended to discontinued due to difficulties executing the study under the COVID-19 pandemic. .
- 20 May 2021 Planned End Date changed from 1 Oct 2021 to 1 Dec 2022.
- 20 May 2021 Planned primary completion date changed from 1 Oct 2021 to 1 Dec 2022.